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Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis, venous thrombosis,
and bone marrow failure. Seventeen patients with debilitating PNH, including 8 who were HLA-
alloimmunized, underwent a reduced-intensity allogeneic hematopoietic cell transplantation (HCT). All
received cyclophosphamide/ﬂudarabine þ/ antithymocyte globulin followed by a granulocyte colony-
stimulating factoremobilized HCT from an HLA-matched relative. Glycosylphosphatidylinositol-negative
neutrophils were detectable after engraftment but disappeared completely at a median 100 days after
transplantation. With a median follow-up of nearly 6 years, 15 patients (87.8%) survived, all without any
evidence of PNH, transfusion independent, and off anticoagulation. Allogeneic reduced-intensity HCT remains
a curative therapeutic option for PNH patients who are not candidates for eculizumab treatment.
 2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a
nonmalignant clonal disorder of hematopoietic stem cells,
characterized by a somatic mutation in the PIG-A gene [1].
Due to a defect in the glycosylphosphatidylinositol (GPI)
anchor, PNH stem cells and their progeny lack GPI-anchored
surface proteins, some of which (eg, CD55 and CD59) protect
erythrocytes from complement-mediated lysis [2]. Patients
with PNH may manifest a variety of symptoms, including
recurrent intravascular hemolysis, venous thrombosis [3],dgments on page 1439.
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14.05.012and hematopoietic failure [4], all of which shorten survival
compared with healthy age-matched controls [5,6].
Eculizumab, a monoclonal antibody to C5a, is highly
effective in preventing both hemolysis and thrombosis
associated with this disorder [7]. However, this agent re-
quires lifelong therapy and may be unaffordable for many
patients. After treatment, low levels of persistent extravas-
cular hemolysis as a consequence of complement C3 opso-
nization can occur, leading to the persistent need for
erythrocyte transfusions in a minority of eculizumab-treated
patients [8]. Furthermore, although eculizumab can be
effective in controlling intravascular hemolysis in PNH pa-
tients with bone marrow failure, it does not improve he-
matopoiesis in these patients, requiring additional therapy,
such as immunosuppression with antithymocyte globulin or
allogeneic hematopoietic cell transplantation (HCT).
Although allogeneic bone marrow transplantation can be
curative for PNH, the procedure has historically been asso-
ciated with high rates of rejection and regimen-related
mortality [9,10]. This is likely the consequence of these pa-
tients being heavily transfused and having a high incidence
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regimens were often more myeloablative than they were
immunosuppressive, and patients typically underwent
transplantation with bone marrow grafts, which contained
lower numbers of CD34þ cells and T cells, all factors that may
have increased the odds of graft rejection. Previously, we
reported that ﬂudarabine-based reduced-intensity (RI)-HCT
could be used to reduce the risk of graft-rejection in heavily
transfused and HLA-alloimmunized patients. Further, we
described that T cells engrafting after RI-HCT can immuno-
logically eradicate PNH through a graft-versus-marrow ef-
fect. Here, we the report long-term outcome on the use of
this approach in 17 patients with severe, debilitating PNH
who underwent an RI-HCT from an HLA-matched relative.
METHODS
Eligibility for transplantation included a diagnosis of PNH with 1 or
more of the following: (1) transfusion dependence, (2) a history of throm-
botic events, or (3) recurrent debilitating hemolytic crises. Patients were
eligible for treatment on this research trial and were included in this anal-
ysis if, by deﬁnition [11], they had classic PNH, or clinical or subclinical PNH
(PNH clone of at least 5%) in the setting of other bone marrow failure
conditions.
Seventeen consecutive patients with PNH underwent a peripheral blood
allogeneic RI-HCT at the National Heart, Lung, and Blood Institute on insti-
tutional review boardeapproved protocol 99-H-0050. Bone marrow failure,
patient preference, or drug unavailability precluded the use of eculizumab in
all patients. Patients received a T cellereplete granulocyte colony-
stimulating factor (G-CSF)emobilized peripheral blood HCT from a 6/6
HLA-matched relative after conditioning with intravenous cyclophospha-
mide 60 mg/kg/day (days 7 and 6) and ﬂudarabine 25 mg/m2/day
(days 5 to 1). To prevent graft rejection, patients with a signiﬁcant
transfusion history had equine antithymocyte globulin (40 mg/kg/day
days 5 to 2) added to the conditioning regimen (n ¼ 14). Graft-versus-
host disease (GVHD) prophylaxis consisted of initially of cyclosporine
(CSA), administered alone (n ¼ 1) or with mycophenolate mofetil 1 g by
mouth twice daily (n ¼ 4). Because an analysis of a similar transplantation
regimen for hematological malignancies demonstrated superiority of com-
bined CSA/methotrexate over CSA/mycophenolate mofetil for reducing
acute GVHD [12], the last 12 PNH patients who underwent transplantation
on this study received CSA combined with methotrexate 5 mg/m2/day given
on days þ1, þ3, and þ6. On day 0, an unmanipulated G-CSFemobilized
peripheral blood allograft (target 5  106 CD34þ cells/kg recipient weight)
from an HLA-identical (6/6) relative was infused. All recipients received
their grafts from an HLA-matched sibling, with the exception of 1 patient
who received an allograft from her HLA-matched mother (patient no. 4).
Peripheral blood samples were collected on post-transplantation days
15, 30, 45, 60, and 100, and monthly thereafter, if necessary to enumerate
the percentage of PNH granulocytes and erythrocytes and to quantitate the
percentage donor chimerism in myeloid and T cell lineages [13]. Complete
donor chimerism was deﬁned as the ﬁrst time to 95% donor-derived cells
in peripheral blood. Patients receiving systemic anticoagulation before
transplantation continued to be anticoagulated after transplantation for 3 to
6 months after GPI-negative neutrophils became undetectable in the blood,
as a protocol-speciﬁed safety requirement to avoid thrombotic events in this
high-risk cohort. Eculizumabwas not used in any patients to reduce the risk
of peri-transplantation hemolysis. Acute GVHD was graded and staged
prospectively, using criteria from the 1994 Consensus Conference on Acute
GVHD Grading. The diagnosis of clinical features of chronic GVHD was
determined prospectively and classiﬁed into limited or extensive based on
the Revised Seattle Classiﬁcation. Overall survival was estimated by the
Kaplan-Meier method, censoring at the last follow-up. The probabilities of
development of acute and chronic GVHD and transplantation-related mor-
tality were estimated using the cumulative incidence methods and
compared using Gray’s test, where death without the speciﬁed event was
considered a competing risk. Analysis was performed using the R statistical
programming software and its cmprsk package (www.r-project.org).
RESULTS
Seventeen patients with PNH, with a median age of 31
(range, 20 to 42 years) underwent transplantation (Table 1).
The median percentage of GPI-negative neutrophils before
transplantation was 81.6% (range, 5.5% to 99%). Indications for
transplantation included PNH-associated bonemarrow failurein 10 patients, including 2 with cytogenetic evidence for
evolution to myelodysplastic syndrome; thrombotic events in
3 patients; and recurrent debilitating hemolysis in 4 patients,
including 2 with erythrocyte-transfusion dependence. Eight
patients (47%) were HLA-alloimmunized before trans-
plantation with a median 76.5% (range, 45% to 100%) panel
reactive antibody. Allografts contained a median
6.7  106 cells/kg (range, 3.1 to 21.1  106) CD34þ cells and
2.5  108 cells/kg CD3þ cells (range, 1.4 to 4.3  108). All pa-
tients engrafted with no graft rejection or late graft failure.
Neutrophil and platelet recovery occurred at amedian 14 days
(range, 9 to 18) and 12 days (range, 5 to 15), respectively.
Chimerism analysis revealed sustained donor engraftment
occurred in both myeloid (CD14þ/CD15þ) and T cell (CD3þ)
lineages in all 17 patients; the median time to achievement of
full donor myeloid and T cell chimerism was 15 and 30 days,
respectively. Sequential peripheral blood ﬂow cytometry
analysis revealed evidence for donor immuneemediated
eradication of PNH (Figure 1A); although GPI-negative neu-
trophils were detectable early in all patients after trans-
plantation, these populations declined and disappeared in all
patients at a median 100 days (range, 30 to 150) after trans-
plantation. The cumulative incidence of grade 2 to 4 acute
GVHD was 47.1% (n ¼ 8) and the cumulative incidence of
chronic GVHD was 70.6% (n ¼ 11). The sample of patients is
too small to draw conclusions on the effect of GVHD pro-
phylaxis regimens on incidence. No thrombotic events
occurred after transplantation. Two patients died, 1 from
complications related to acute GVHD (day 169) and 1 from
complications of a perforated peptic ulcer 2.8 years later. With
a median follow-up of nearly 6 years (range, 2.6 to 11 years),
15 patients (87.8%) survive without any evidence of PNH,
transfusion independent, and off anticoagulation (Figure 1B).
DISCUSSION
Although allogeneic HCT can be curative for PNH, there is
a substantial risk of mortality [9,14,15] and graft rejection
with conventional myeloablative bone marrow trans-
plantation (BMT). Data from a pilot trial evaluating RI-HCT
for PNH provided the ﬁrst evidence that engrafting donor
T cells could eradicate abnormal recipient stem cells through
a graft-versus-marrow effect, obviating the need for poten-
tially toxic myeloablative conditioning [16]. The current
report published here reﬂects the largest single-institution
experience to date of RI peripheral-blood HCT for PNH.
Although the optimal transplantation paradigm for this
population has not been deﬁned, the excellent outcome and
long-term survival observed in our cohort suggest this
approach can be used to overcome the high risk of graft
rejection that has historically contributed to the poor
outcome associated with conventional BMT for PNH. Despite
nearly one half of the patients in this series being HLA
alloimmunized, all achieved sustained donor engraftment
with none experiencing graft rejection, graft failure, or
relapse of their PNH. The profound recipient lympho-
depletion achieved with ﬂudarabine/cyclophosphamide
and ATG conditioning, combined with the transplantation of
an allograft containing high numbers of donor CD34þ cells
and T cells, likely led to rapid donor T cell engraftment that
eradicated both PNH-type recipient stem cells and host
T cells that mediate graft rejection.
Although the incidence of both acute and chronic GVHD
was high in this series, only 1 patient died from early
transplantation-related complications, with long-term sur-
vival being excellent at 88% with almost 6 years median
Table 1
Patient Characteristics, Clinical Features, and Transplantation Outcomes
Patient
No.
Age at
Transplantation
Sex Diagnosis Clinical Features Pretransplantation
HLA
Alloimmunization
(% PRA)
Pretransplantation %
GPI-Negative
Neutrophils
Equine ATG
with
Conditioning
GVHD
Prophylaxis
Acute
GVHD
Chronic
GVHD
Follow-
up, yr
Discontinuation
of IST, yr
Survival
Status
1 31 M PNH Hemolysis and
thrombosis
(portal vein), TD
Yes (46%) 92.0 Yes CSA None Extensive 11.0 8.6 Alive
2 25 F PNH Hemolysis and
cytopenia, TD
Yes (68%) 97.0 Yes CSAþMMF None Limited 9.2 1.0 Alive
3 35 M PNH Hemolysis and
cytopenia, TD
No 92.0 Yes CSAþMMF Grade 3-4,
SR
Extensive 2.8 On IST at
last follow-up
Dead
4 27 F PNH Hemolysis and
cytopenia, TD
Yes (45%) 13.0 Yes CSAþMMF Grade 3-4 Limited 8.2 3.1 Alive
5 35 M PNH Hemolysis and
thrombosis
(portal vein)
No 92.0 Yes CSAþMMF None None 2.6 Not applicable Alive
6 31 M PNH/SAA Cytopenia, TD No 91.0 Yes CSAþMTX Grade 3-4,
SR
Extensive 7.3 5.5 Alive
7 42 F PNH/
MDS
Cytopenia and
IPSS Int-1MDS
t(1;13), TD
Yes (98%) 86.2 Yes CSAþMTX None Extensive 6.7 5.1 Alive
8 21 M PNH Cytopenia, TD Yes (95%) 22.0 Yes CSAþMTX Grade 3-4,
SR
Limited 6.0 2.2 Alive
9 34 M PNH Hemolysis and
thrombosis
(cerebrovascular)
No 99.0 No CSAþMTX None Extensive 5.9 On IST at
last follow-up
Alive
10 32 M PNH Hemolysis No 74.0 No CSAþMTX Grade 3-4,
SR
Extensive 5.9 On IST at
last follow-up
Alive
11 34 F PNH Hemolysis and
cytopenia, TD
Yes (85%) 56.0 Yes CSAþMTX Grade 3-4,
SR
Not
applicable
169 d Not applicable Dead
(acute
GVHD
TRM)
12 33 M PNH Hemolysis, TD Yes (100%) 99.0 Yes CSAþMTX None None 5.6 Not applicable Alive
13 23 M PNH/
MDS
Cytopenia and IPSS
Int-1 MDS del13q, TD
Yes (55%) 5.5 Yes CSAþMTX Grade 3-4,
SR
Extensive 3.4 On IST at
last follow-up
Alive
14 20 M PNH/SAA Cytopenia, TD No 46.0 Yes CSAþMTX None None 3.4 Not applicable Alive
15 24 M PNH/SAA Cytopenia, TD No 81.6 Yes CSAþMTX None Limited 4.0 2.1 Alive
16 37 M PNH/SAA Hemolysis, TD No 41.0 Yes CSAþMTX None None 3.9 Not applicable Alive
17 20 M PNH Hemolysis No 71.2 No CSAþMTX Grade 2 None 3.3 Not applicable Alive
PRA indicates panel reactive antibody; ATG, antithymocyte globulin; IST, immunosuppressive therapy; M, male; TD, transfusion-dependent on red cells and/or platelets; F, female; MMF, mycophenolate mofetil; SAA, severe
aplastic anemia; SR, steroid refractory; MTX, methotrexate; MDS, myelodysplastic syndrome; IPSS, International Prognostic Scoring System; Int-1, intermediate-1, TRM, transplantation-related mortality.
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Figure 1. (A) Summary of GPI-negative neutrophil eradication. (B) Transplantation outcomes in 17 patients with PNH.
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in 7 of 11 (63%) patients, allowing discontinuation of all
immunosuppressive therapy at a median 3.1 years (range, 1
to 8.6) after transplantation. Previously, we and others have
presented in vitro and in vivo data showing PNH cells are
sensitive to immunological eradication by allo-reactive
donor T cells [17,18]. The long-term follow-up data pre-
sented here provide deﬁnitive evidence that PNH can be
cured by this immunological effect. Further, we show these
immune-mediated remissions are durable, are not associated
with the recurrence of PNH, allow patients to discontinue
anticoagulation without recurrent thrombosis, and result in
excellent long-term survival in patients who historically
would be at high risk for treatment failure and death with a
conventional allogeneic BMT.
Recently, the largest retrospective analysis published to
date on HCT in 211 patients with PNH who underwent trans-
plantation at 83 different European Group for Blood and
Marrow Transplantation (EBMT) centers using registry data
suggested inferior survival compared with matched patients
who did not undergo transplantation [10]. The only predictor
of transplantation outcome identiﬁed in that study was theindication for transplantation; recipients who experienced
thrombotic events had the worst outcome, with only a 57% 5-
year survival. In contrast to that analysis, ourprospective study
involved a cohort of PNH patients treated at a single center
who all received the same ﬂudarabine-based RI trans-
plantation approach, whichwas tailored speciﬁcally for use in
bonemarrow failure syndromes associatedwith a high risk of
graft rejection. Of note, all 3 patients in our analysis who had
thrombosis as an indication for transplantation had long-term
survival. However, the relatively small size of our patient
cohort and their excellent long-term survival precluded us
from conducting a multivariate investigation of disease-
speciﬁc predictors of outcome. To date, there is no prospec-
tive intent-to-treat study comparing transplantation versus
eculizumab in the management of patients with PNH. Eculi-
zumab’s high efﬁcacy and established safety have precluded
such a study, given the risk of mortality associated with stem
cell transplantation. Despite eculizumab’s inarguable success
as being a highly effective therapy for PNH, there remains a
subset of patients who cannot be managed lifelong with this
drug because of either lack of access, unwillingness to be
committed to lifelong treatment, or the persistent need for
J. Pantin et al. / Biol Blood Marrow Transplant 20 (2014) 1435e1454 1439erythrocyte transfusion,despite therapy.Moreover, inpatients
with PNH and bone marrow failure, improvement in hema-
topoiesis does not occur with this therapy. Eculizumab, which
is 1 of theworld’smost expensivemedications, is prohibitively
expensive for patients without medical insurance. Although
the cost of allogeneic transplantation can vary substantially
depending on the transplantation approach utilized and the
presence or absence of post-transplantation complications, a
recent studyestimated amedian cost of aboutUS $200,000 for
the ﬁrst 100 days of care after allogeneic HCT [19]. Therefore,
HCTasa curative treatmentmodality thatobviates theneed for
lifelong therapy for PNH costing $400,000 per patient year
should be appreciated as being remarkably cost-effective [20].
The 15 patients in our study, whowere cured of PNH andwho
have long-term survival, represent a $6,000,000 annual cost
avoidance, with the potential total savings on this drug being
extraordinarywhen considering theexpected longevity of this
relatively young cohort (median age, 31 years). In the context
of our long-term follow-up study showing excellent survival
and a high probability of cure, these ﬁnancial considerations
further support ﬂudarabine-based RI-HCTas viable treatment
option for selected PNH patients.
In this study, which utilized G-CSFemobilized peripheral
blood progenitor cells as the graft source, there was an un-
acceptably high incidence of chronic GVHD. Subsequent
studies have clearly demonstrated the superiority in reduced
incidence of GVHD with bone marrow as the preferred graft
source in other bone marrow failure conditions [21]. T cell
depletion after peripheral blood HCT using a variety of
different in vitro and in vivo strategies has demonstrated
success in lowering the incidence of chronic GVHD after
peripheral blood HCT for severe aplastic anemia [22-24],
although in some cases, the risk of graft rejection has been
excessively high [25]. To reduce the risk of rejection in allo-
geneic HCT for PNH and aplastic anemia associated with
complete ex vivoTcell depletion or uncontrolled in vivoTcell
depletion, we are exploring a strategy whereby high
numbers of mobilized CD34þ selected peripheral blood cells
are combined with nonmobilized T cells at a T cell dose that
matches cell numbers typically infused after a bone marrow
harvest (ClinicalTrials.gov identiﬁer: NCT01174108).
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